

18. Marzolini C, Kuritzkes DR, Marra F, et al. Prescribing Nirmatrelvir-Ritonavir: how to recognize and manage drug-drug interactions. *Ann Intern Med.* 2022;175:744-746.
19. Abraham S, Nohria A, Neilan TG, et al. Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2022;80(20):1912-1924.
20. Wang Z, Chun Young Chan E. Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating nirmatrelvir/ritonavir (Paxlovid) for COVID-19 treatment. *Clin Pharmacol Ther.* 2022;112(4):803-807.
21. Vazquez SR, Wilson AS, Witt DM. Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series. *J Thromb Thrombolysis.* 2022;54(4):583-586.
22. Ross SB, Bortolussi-Courval É, Hanula R, et al. Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications. *JAMA Netw Open.* 2022;5(7):e2220184.
23. Gerhart J, Draica F, Benigno M, et al. Real world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir. *The AAPS J.* 2023;25:73.
24. Vuorio A, Kovanen PT, Raal F. Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid therapy. *Future Virol.* 2022. doi: 10.2217/fvl-2022-0060.
25. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, et al. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. *JAAC.* 2021;78(16):1635-1654.
26. Haque OI, Mahar S, Hussain S, et al. Pharmacokinetic interaction between verapamil and ritonavir boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. *BMJ Case Rep.* 2023;16:e252677.
27. Shini Rubina SK, Anuba PA, Swetha B, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases. *Diabetes Metab Syndr.* 2022;16(3):102451.